{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:16:05Z","timestamp":1792430165867,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81801804"],"award-info":[{"award-number":["No.81801804"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The presence of liver metastasis correlates with poor therapeutic response of PD-1 blockade therapy in melanoma. A novel treatment protocol by combining cryoablation with transarterial infusion of pembrolizumab (CATAP) was proposed, and its feasibility and safety was assessed among this group of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This registered ambispective cohort study enrolled fifteen melanoma patients with multiple hepatic metastases who received planned two-stage CATAP therapy: in the combined stage, subtotal cryoablation on day 1, in which one to two intrahepatic lesions were ablated completely with other lesions left untreated, sequentially combined transarterial infusion of pembrolizumab on day 3, every three weeks, for at least one cycle; in the infusion stage, arterial infusion of pembrolizumab was recommended at three-week interval until disease progression. The primary endpoint was objective response rate by RECIST (version 1.1); secondary end points included progression-free survival (PFS) and safety; exploratory endpoints were changes of cytokines and immune cell compositions in peripheral blood samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 15 patients enrolled, no grade 3\u20134 adverse events or major complications were observed. One patient (6.7%) achieved complete response, and 3 (20.0%) achieved partial response. The overall response rates of CATAP for the entire cohort and patients with cutaneous melanoma were 26.7% (95% confidence interval (CI) 4.3\u201349.0%) and 33.3% (95% CI 2.5\u201364.1%), respectively. Clinical response was observed in a proportion of patients (2\/6; 33.3%) who failed first-line intravenous pembrolizumab treatment. The median overall PFS time and hepatic PFS time were 4.0 (95% CI 2.5\u20135.5) and 5.73 (95% CI 1.1\u201310.4) months, respectively. A significant increase in CD3-CD16\u2009+\u2009CD56\u2009+\u2009cells (natural killer cells;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0124) and a marginally significant decrease in CD4\u2009+\u2009CD25\u2009+\u2009cells (regulatory T cells;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0546) were observed three weeks after the first cycle of treatment in the combined stage.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The CATAP therapy demonstrated positive clinical activity and a favorable\u00a0safety\u00a0profile for melanoma patients with liver metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-020-02566-z","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T10:03:37Z","timestamp":1587722617000},"page":"1713-1724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study"],"prefix":"10.1007","volume":"69","author":[{"given":"Lujun","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanggang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"2566_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J et al (2019) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. The Lancet Oncol 20:1239\u20131251. https:\/\/doi.org\/10.1016\/S1470-2045(19)30388-2","journal-title":"The Lancet Oncol"},{"key":"2566_CR2","doi-asserted-by":"publisher","first-page":"3264217","DOI":"10.1155\/2017\/3264217","volume":"2017","author":"C Rodriguez-Cerdeira","year":"2017","unstructured":"Rodriguez-Cerdeira C, Carnero Gregorio M, Lopez-Barcenas A, Sanchez-Blanco E, Sanchez-Blanco B, Fabbrocini G, Bardhi B, Sinani A, Guzman RA (2017) Advances in immunotherapy for melanoma: a comprehensive review. Mediators Inflamm 2017:3264217. https:\/\/doi.org\/10.1155\/2017\/3264217","journal-title":"Mediators Inflamm"},{"key":"2566_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109\u20131117. https:\/\/doi.org\/10.1016\/S0140-6736(14)60958-2","journal-title":"Lancet"},{"key":"2566_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh PC, Hellmann MD, Hamid O et al (2017) Liver metastasis and treatment outcome with Anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 5:417\u2013424. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0325","journal-title":"Cancer Immunol Res"},{"key":"2566_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/0168-8278(95)80433-1","volume":"22","author":"P Knolle","year":"1995","unstructured":"Knolle P, Schlaak J, Uhrig A, Kempf P, Meyer zum Buschenfelde KH, Gerken G (1995) Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol 22:226\u2013229","journal-title":"J Hepatol"},{"key":"2566_CR6","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ni.2691","volume":"14","author":"CN Jenne","year":"2013","unstructured":"Jenne CN, Kubes P (2013) Immune surveillance by the liver. Nat Immunol 14:996\u20131006. https:\/\/doi.org\/10.1038\/ni.2691","journal-title":"Nat Immunol"},{"key":"2566_CR7","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.4049\/jimmunol.172.9.5222","volume":"172","author":"B John","year":"2004","unstructured":"John B, Crispe IN (2004) Passive and active mechanisms trap activated CD8+ T cells in the liver. J Immunol 172:5222\u20135229","journal-title":"J Immunol"},{"key":"2566_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2217\/imt.13.158","volume":"6","author":"JP Almeida","year":"2014","unstructured":"Almeida JP, Drezek RA, Foster AE (2014) Controlling melanoma at local and systemic levels: is a combination of ablative therapy and immunotherapy the way forward? Immunotherapy 6:109\u2013111. https:\/\/doi.org\/10.2217\/imt.13.158","journal-title":"Immunotherapy"},{"key":"2566_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrc3672","volume":"14","author":"KF Chu","year":"2014","unstructured":"Chu KF, Dupuy DE (2014) Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 14:199\u2013208. https:\/\/doi.org\/10.1038\/nrc3672","journal-title":"Nat Rev Cancer"},{"key":"2566_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fonc.2018.00085","volume":"8","author":"J Abdo","year":"2018","unstructured":"Abdo J, Cornell DL, Mittal SK, Agrawal DK (2018) Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers. Front Oncol 8:85. https:\/\/doi.org\/10.3389\/fonc.2018.00085","journal-title":"Front Oncol"},{"key":"2566_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.crad.2013.09.014","volume":"69","author":"W Zhang","year":"2014","unstructured":"Zhang W, Yu H, Guo Z, Li B, Si T, Yang X, Wang H (2014) Percutaneous cryoablation of liver metastases from breast cancer: initial experience in 17 patients. Clin Radiol 69:231\u2013238. https:\/\/doi.org\/10.1016\/j.crad.2013.09.014","journal-title":"Clin Radiol"},{"key":"2566_CR12","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00270-016-1384-4","volume":"39","author":"GM Kim","year":"2016","unstructured":"Kim GM, Won JY, Kim MD et al (2016) Cryoablation of hepatocellular carcinoma with high-risk for percutaneous ablation: safety and efficacy. Cardiovasc Interv Radiol 39:1447\u20131454. https:\/\/doi.org\/10.1007\/s00270-016-1384-4","journal-title":"Cardiovasc Interv Radiol"},{"key":"2566_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cryobiol.2013.10.005","volume":"67","author":"L Xin'an","year":"2013","unstructured":"Xin'an L, Jianying Z, Lizhi N, Fei Y, Xiaohua W, Jibing C, Jialiang L, Kecheng X (2013) Alleviating the pain of unresectable hepatic tumors by percutaneous cryoablation: experience in 73 patients. Cryobiology 67:369\u2013373","journal-title":"Cryobiology"},{"key":"2566_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/jso.23551","volume":"109","author":"S Lodh","year":"2014","unstructured":"Lodh S, Maher R, Guminski A (2014) Intra-arterial infusion and chemo-embolization for melanoma liver metastases. J Surg Oncol 109:376\u2013382. https:\/\/doi.org\/10.1002\/jso.23551","journal-title":"J Surg Oncol"},{"key":"2566_CR15","first-page":"1550","volume":"53","author":"JN Munck","year":"1993","unstructured":"Munck JN, Riggi M, Rougier P et al (1993) Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model. Cancer Res 53:1550\u20131554","journal-title":"Cancer Res"},{"key":"2566_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10585-011-9432-6","volume":"29","author":"J Sperling","year":"2012","unstructured":"Sperling J, Schafer T, Ziemann C, Benz-Weiber A, Kollmar O, Schilling MK, Menger MD (2012) Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clin Exp Metastasis 29:91\u201399. https:\/\/doi.org\/10.1007\/s10585-011-9432-6","journal-title":"Clin Exp Metastasis"},{"key":"2566_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2566_CR18","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi AP, Tsai KK, Shoushtari AN et al (2016) Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 122:3344\u20133353. https:\/\/doi.org\/10.1002\/cncr.30258","journal-title":"Cancer"},{"key":"2566_CR19","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00262-017-1989-8","volume":"66","author":"X Wen","year":"2017","unstructured":"Wen X, Ding Y, Li J et al (2017) The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series. Cancer Immunol Immunother CII 66:1153\u20131162. https:\/\/doi.org\/10.1007\/s00262-017-1989-8","journal-title":"Cancer Immunol Immunother CII"},{"key":"2566_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"2566_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"2566_CR22","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1002\/cncr.28282","volume":"119","author":"JJ Luke","year":"2013","unstructured":"Luke JJ, Callahan MK, Postow MA et al (2013) Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 119:3687\u20133695. https:\/\/doi.org\/10.1002\/cncr.28282","journal-title":"Cancer"},{"key":"2566_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.6004\/jnccn.2018.7070","volume":"17","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Bao R, Ancell KK, Daniels AB, Wallace D, Sosman JA, Luke JJ (2019) Response to anti\u2013PD-1 in uveal melanoma without high-volume liver metastasis. J Natl Compr Cancer Netw 17:114\u2013117. https:\/\/doi.org\/10.6004\/jnccn.2018.7070","journal-title":"J Natl Compr Cancer Netw"},{"key":"2566_CR24","doi-asserted-by":"publisher","first-page":"9137","DOI":"10.1007\/s13277-015-4126-3","volume":"36","author":"C Bastianpillai","year":"2015","unstructured":"Bastianpillai C, Petrides N, Shah T, Guillaumier S, Ahmed HU, Arya M (2015) Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment. Tumour Biol 36:9137\u20139146. https:\/\/doi.org\/10.1007\/s13277-015-4126-3","journal-title":"Tumour Biol"},{"key":"2566_CR25","doi-asserted-by":"publisher","first-page":"e1537581","DOI":"10.1080\/2162402X.2018.1537581","volume":"8","author":"H Lee","year":"2019","unstructured":"Lee H, Quek C, Silva I et al (2019) Integrated molecular and immunophenotypic analysis of NK cells in anti\u2013PD-1 treated metastatic melanoma patients. Oncoimmunology 8:e1537581. https:\/\/doi.org\/10.1080\/2162402X.2018.1537581","journal-title":"Oncoimmunology"},{"key":"2566_CR26","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry KC, Hsu J, Broz ML et al (2018) A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med 24:1178\u20131191. https:\/\/doi.org\/10.1038\/s41591-018-0085-8","journal-title":"Nat Med"},{"key":"2566_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18379","author":"T Gambichler","year":"2019","unstructured":"Gambichler T, Schroter U, Hoxtermann S, Susok L, Stockfleth E, Becker JC (2019) Decline of PD-1 positive circulating T regulatory cells predicting more favorable clinical outcome of melanoma patients under immune checkpoint blockade. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.18379","journal-title":"Br J Dermatol"},{"key":"2566_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CJI.0000000000000277","volume":"42","author":"T Gambichler","year":"2019","unstructured":"Gambichler T, Schroter U, Hoxtermann S, Susok L, Stockfleth E, Becker JC (2019) A brief communication on circulating PD-1-positive T-regulatory lymphocytes in melanoma patients undergoing adjuvant immunotherapy with nivolumab. J Immunother 42:265\u2013268. https:\/\/doi.org\/10.1097\/CJI.0000000000000277","journal-title":"J Immunother"},{"key":"2566_CR29","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","volume":"24","author":"RW Joseph","year":"2018","unstructured":"Joseph RW, Elassaiss-Schaap J, Kefford R et al (2018) Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res 24:4960\u20134967. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2386","journal-title":"Clin Cancer Res"},{"key":"2566_CR30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375:819\u2013829. https:\/\/doi.org\/10.1056\/NEJMoa1604958","journal-title":"N Engl J Med"},{"key":"2566_CR31","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","volume":"168","author":"W Hugo","year":"2017","unstructured":"Hugo W, Zaretsky JM, Sun L et al (2017) Genomic and transcriptomic features of response to anti\u2013PD-1 therapy in metastatic melanoma. Cell 168:542. https:\/\/doi.org\/10.1016\/j.cell.2017.01.010","journal-title":"Cell"},{"key":"2566_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0659-0","author":"A Forschner","year":"2019","unstructured":"Forschner A, Battke F, Hadaschik D et al (2019) Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma\u2014results of a prospective biomarker study. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-019-0659-0","journal-title":"J Immunother Cancer"},{"key":"2566_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/medsci7020014","author":"T Seto","year":"2019","unstructured":"Seto T, Sam D, Pan M (2019) Mechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer. Med Sci (Basel). https:\/\/doi.org\/10.3390\/medsci7020014","journal-title":"Med Sci (Basel)"},{"key":"2566_CR34","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532. https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"2566_CR35","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1046\/j.1440-1746.2003.02991.x","volume":"18","author":"KK Ng","year":"2003","unstructured":"Ng KK, Lam CM, Poon RT, Ai V, Tso WK, Fan ST (2003) Thermal ablative therapy for malignant liver tumors: a critical appraisal. J Gastroenterol Hepatol 18:616\u2013629. https:\/\/doi.org\/10.1046\/j.1440-1746.2003.02991.x","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02566-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02566-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02566-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T01:11:04Z","timestamp":1619313064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02566-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2566"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02566-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"16 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}}]}}